Leap Technologies and Antec Announce HDX–MS Venture
Leap Technologies Inc. and Antec have announced a joint venture in the field of sample preparation for HDX–MS.
Leap Technologies Inc. (Carrboro, USA) and Antec (Zoeterwoude, The Netherlands) have announced a joint venture in the field of sample preparation for hydrogen deuterium exchangeâmass spectrometry (HDXâMS).
“We are excited to collaborate with LEAP the world leader in HDX automation and to bring HDX/MS to a new level of customer satisfaction by integrating the disulfide bond reduction,” said Jean-Pierre Chervet, CEO of Antec.
The integration of Leap Technologies’ automated workstation with Antec’s electrochemical mass spectrometry system will provide a fully automated hydrogen deuterium exchange electrochemical mass spectrometry workflow that can be used with mass spectrometers.
This full integration decreases the time required to reduce the disulphide bonds in proteins/peptides when using reducing agents such as TCEP. This is particularly useful for large and highly disupfide-stabilised proteins, enabling HDX analysis and resulting in increased overall sequence coverage.
Leap and Antec will be presenting this approach at the American Society for Mass Spectrometry conference (ASMS) in San Antonio, Texas, USA, June 5â9.
For more information about Antec visit www.myantec.com
For more information about Leap Technologies visit www.leaptec.com
New TRC Facility Accelerates Innovation and Delivery
April 25th 2025We’ve expanded our capabilities with a state-of-the-art, 200,000 sq ft TRC facility in Toronto, completed in 2024 and staffed by over 100 PhD- and MSc-level scientists. This investment enables the development of more innovative compounds, a broader catalogue and custom offering, and streamlined operations for faster delivery. • Our extensive range of over 100,000 high-quality research chemicals—including APIs, metabolites, and impurities in both native and stable isotope-labelled forms—provides essential tools for uncovering molecular disease mechanisms and exploring new opportunities for therapeutic intervention.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
